TP53 and cancer: A novel, selective RNA pol I transcription inhibitor, CX-5461 (Cylene Pharmaceuticals/Senhwa Biosciences), promotes cancer-specific activation of p53 and apoptosis in malignant B cells [28], which is an interesting development in the search for new anti-cancer therapies.